Search alternatives:
ng decrease » _ decrease (Expand Search), a decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
ng decrease » _ decrease (Expand Search), a decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
-
2721
-
2722
Recognition by the Cf-4 immune receptor and susceptibility to proteolytic degradation of the WT-<i>Cf</i>Avr4 and selected ChBD and (GlcNAc)<sub>6</sub>-binding mutants.
Published 2018“…<b>(C)</b> Treatment of the WT-<i>Cf</i>Avr4 and Q69N, N93A, D94A, and D102A mutants with 500 ng/μl subtilisin, digests the original full-length protein (blue arrows) to a smaller product that corresponds to the true mature form of <i>Cf</i>Avr4 (red arrows). …”
-
2723
-
2724
A model for SOX9 control of differentiation phase–specific gene expression in growth plate chondrocytes.
Published 2011“…<i>Col2a1</i> transcription may be maintained due to stabilization of SOX9 binding by SOX5/6 <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1002356#pgen.1002356-Han1" target="_blank">[15]</a>. …”
-
2725
Additional file 1 of MDM2-amplified esophageal adenocarcinomas exhibit an activated metabolic and immunosuppressive phenotype with multiple potential therapeutic targets
Published 2025“…The column names are given the MDM2 amplification status of each sample (MDM2-amplified: MDM2 +; MDM2-non-amplified: NEG.; non tumor tissue: N.G). Additionally, the columns are labeled whether the tumor was treated neoadjuvant (Neoadjuvant) or primarily resected (Primary). …”
-
2726
-
2727
-
2728
-
2729
-
2730
-
2731
-
2732
-
2733
-
2734
-
2735
-
2736
-
2737
-
2738
-
2739
-
2740